Semax was developed by a Moscow research team that included Igor Ashmarin and Nikolai Myasoedov. The work joined the Institute of Molecular Genetics and Moscow State University during the Soviet era. They were looking for a way to study memory and attention without reproducing a hormone's usual effects.
So, who discovered Semax? A team designed it; nobody found it growing in nature. Semax is a synthetic peptide, a laboratory-made chain of seven amino acids, the building blocks of proteins.
Who discovered Semax, and what were they looking for?
Ashmarin and Myasoedov are the names most associated with Semax, but the published record credits a larger group. Moscow State University's departmental award record names both among the collaborators recognized for developing the medicine.
The Institute of Molecular Genetics belonged to the USSR Academy of Sciences when the early work appeared. Later publications identify it with the Russian Academy of Sciences. Calling the original project Russian is familiar shorthand, but its beginnings were Soviet.
In a 2004 account written by Ashmarin, Myasoedov and colleagues, they describe research begun in the late 1970s. The question was how to support brain function under demanding conditions. Short pieces of ACTH offered a starting point. ACTH signals glands above the kidneys to release cortisol, a hormone involved in the stress response.
Natural ACTH fragments broke down quickly. The team's problem was partly chemical: could they change the fragment enough to make it last longer?
How Semax got its name and its seven building blocks
The developers explained the name as a shortened form of the Russian words for “seven amino acids.” It describes the molecule's length, not a dose or a claim about maximum performance.
Semax is often called an ACTH(4–10) analogue, meaning a modified version of positions four through ten in that hormone. But it doesn't keep that whole natural sequence.
It keeps positions four through seven, then uses Pro-Gly-Pro as its final three building blocks. Those abbreviations mean proline, glycine and proline. The tail replaces the natural fragment's last three positions; it isn't added to an intact seven-part fragment.
A 1991 experiment by Potaman and colleagues in Biochemical and Biophysical Research Communications compared breakdown in rat blood and serum, the fluid left after blood clots. Semax resisted some of the enzymes better than the natural ACTH fragment. Enzymes are proteins that speed chemical reactions, including peptide breakdown.
That explains the design. It doesn't establish how long Semax lasts in a person. The separate guide to how Semax works follows the later biological research.
The first papers and the early human studies
The paper trail reaches back well before today's online interest. A July 1984 paper in Pharmaceutical Chemistry Journal described a long-acting ACTH analogue studied for learning. M. A. Ponomareva-Stepnaya was the first author, and Ashmarin was among the collaborators. Its institutional affiliations name both the institute and Moscow University.
A March 1986 PubMed-indexed report examined the modified fragment's hormonal activity in laboratory and animal testing. It reported no steroid-producing or pigment-cell-stimulating activity in those tests. That was a narrow finding about hormone effects, not a broad safety guarantee.
An early human paper appeared in September–October 1996. Kaplan and colleagues, in Neuroscience Research Communications, studied operator performance and EEG, a recording of the brain's electrical activity.
The paper described small experiments in healthy volunteers and operators, some comparing Semax with a placebo, a preparation without the peptide.
The authors reported differences in task performance and brain recordings after nasal administration. These small, short experiments help explain the interest in Semax. They don't establish lasting improvement in everyday memory or concentration.
From the laboratory to a registered Russian medicine
Semax's history includes a real medicine registration. Russia's Ministry of Health and Medical Industry authorized a 0.1% Semax solution through Order No. 294 on December 20, 1994. The order's text, preserved in the GARANT legal archive, identifies registration certificate 94/294/10.
That date matters because registration, publication and production are different milestones. The 1996 human paper wasn't the beginning of the project, and publication didn't mark its Russian registration.
The registered preparation was given through the nose. Its history belongs to particular Russian products and clinical settings. The guide to what Semax is used for explains those uses and their evidence limits.
Selank came from a related Russian peptide-development program but started with tuftsin, a short immune-signaling peptide; what Selank is used for follows that separate story.
The shared research tradition helps explain why the names now appear together. A Semax/Selank prescription is still a different preparation from the single-ingredient Semax used in the early experiments.
From Russian registration to U.S. interest
A Russian registration applies to the Russian product. It doesn't establish that a U.S. preparation meets the evidence and manufacturing standards used by FDA.
History alone can't answer the questions about a new preparation. The early human experiments described above didn't test Semax/Selank or establish lasting benefits in everyday life. A familiar ingredient name doesn't fill those gaps.
The same care applies to newer names. N-acetyl Semax amidate is a chemically modified version, not simply another spelling of the original peptide. Its history and evidence cannot be substituted for standard Semax's.
Where Semax stands today
As of October 1, 2026, the day this article was written, the July 24 FDA advisory vote is part of Semax's U.S. history. The official recording shows eight votes in favor, five against and one abstention for listing Semax free base, the form without an added salt. The recommendation concerned the 503A Bulks List, an ingredient list for certain individually compounded prescriptions. It went against FDA staff's assessment dated May 11, 2026. That advisory vote did not approve a finished medicine; Semax's FDA history follows the regulatory record.
The Semax/Selank blend is offered through Promise after a licensed provider reviews your request, and is dispensed as a compounded injectable vial, prepared by a pharmacy for an individual prescription. That is different from an FDA-approved product: the formulation offered here is not FDA-approved.
What the prescription route adds
A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.
A prescription connects the proposed preparation with a medical history, an identified pharmacy and a follow-up plan. It doesn't turn the early studies into proof for a different formulation or a different goal.
At Promise, a licensed provider reviews every request, and not everyone qualifies. The reviewing clinician decides whether the request fits the person's history and sets any dose and follow-up. The Semax/Selank card above connects that conversation to the current product page.
